In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members

The randomized physiologic assessment of thrombus aspiration in patients with acute myocardial infarction with ST-segment elevation (PATA STEMI)

Session Oral abstract session: PPCI , risk factors and prevention

Speaker Velisava Perovic

Congress : EuroHeartCare 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes - Treatment
  • Session type : Abstract Session
  • FP Number : 246

Authors : V Perovic (Belgrade,RS)

V Perovic1 , 1Dedinje Cardiovascular Institute, Belgrade University School of Medicine - Belgrade - Serbia ,

European Journal of Cardiovascular Nursing ( 2017 ) 17 ( Supplement ), S72

Background: Routine thrombus aspiration is superior to conventional primary percutaneous coronary intervention (PCI) in terms of improved myocardial perfusion in patients with acute myocardial infarction with ST-segment elevation (STEMI), but its clinical usefulness is still questionable. Myocardial perfusion after thrombus aspiration has not been evaluated by a quantitative index of microcirculatory resistance (IMR) in a randomised fashion.
Purpose: We performed a randomized, controlled clinical trial to evaluate impact of manual thrombus aspiration on microcirculatory resistance after primary PCI in 128 patients with the first STEMI randomly assigned to thrombus aspiration or conventional primary PCI group before coronary angiography.
Methods: The primary endpoint was defined as a mean value of IMRcorr in thrombus aspiration compared to conventional PCI group. Myocardial perfusion grade, resolution of ST-segment elevation, enzymatic infarct size, left ventricle remodeling and rate of adverse cardiac events were secondary endpoints.
Results: Manual thrombus aspiration, as compared with conventional PCI, resulted in significantly lower IMR corr (27.5±16,8 U vs. 39,9±32,7 U, P = 0,039). Treatment with thrombus aspiration, as compared with conventional PCI, resulted in similar rates of myocardial perfusion grade 0 or 1 (21,5% vs. 28,6%; RR 0,75; 95% CI, 0,41 to 1,38; P=0,36), complete resolution of ST-segment elevation (61,5% vs. 49,2%; RR 1,25; 95% CI, 0,91 to 1,71, P=0,16), similar infarct size (median AUC CK-MB: 4362 U/L (IQR: 696 to 15636 U/L) versus 4401 U/L (IQR: 996 to 15657 U/L), p=0.27), similar median value of WMSI (1,23 vs 1,23), LV sphericity volume index (0,43 vs. 0,41) and similar rate of LV remodeling (27,9 vs 18,5%, p=0,21). The rate of major adverse events (death, myocardial infarction, stroke or hospitalization for heart failure) between the groups was similar 4,6% vs, 11,1%, P=0,20. In a multiple regression model with the log-transformed IMR as dependent variable, after adjusting for clinical, angiographic and procedural variables, thrombus aspiration was not an independent predictor of lower IMR (28.4 U; 95% CI, 24.7 to 32.8 U, vs. 32.4 U; 95% CI, 28.1 to 37.4 U; estimate 0,877, 95%CI 0,715-1,077, P=0.21).
Conclusions: In our study, manual thrombus aspiration has nodeleterious effect on final infarct size. Although, routine thrombus aspiration leads to improvement in myocardial perfusion,it is not translated into increased myocardial salvage or lower final infarct size compared to standard pPCI.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are